Rene B Hen

20040247525, Dec 9, 2004

Jan 22, 2004

10/764068

Rene Hen - Tenafly NJ, US
Luca Santarelli - New York NY, US
Michael Saxe - New York NY, US

A61K049/00

424/009200, 800/009000

This invention provides methods for determining whether an agent increases brain progenitor cell division in a subject. Furthermore, this invention provides methods for treating anxiety, depression, a cognitive disorder or a neuro-degenerative disorder or inhibiting the onset of anxiety, depression or a cognitive disorder by administering to an afflicted subject a therapeutically or prophylactically effective amount of the agent. Finally, this invention provides methods for treating anxiety, depression, a cognitive disorder or a neuro-degenerative disorder or inhibiting the onset of anxiety, depression or a cognitive disorder by administering to an afflicted subject a therapeutically or prophylactically effective amount of Hh-Ag 1.1, Hh-Ag 1.2, Hh-Ag 1.3, or a derivative of Hh-Ag 1.1, Hh-Ag 1.2 or Hh-Ag 1.3.

20050186137, Aug 25, 2005

Oct 29, 2004

10/977911

Rene Hen - Tenafly NJ, US
Stephanie Dulawa - New York NY, US

A61K049/00

424009100

This invention provides a method for determining whether an agent reduces anxiety and/or depression in a depressed, non-human subject. This invention also provides methods for treating anxiety and depression in subjects afflicted with those disorders comprising administering a therapeutically effective amount of an anxiety-reducing or depression-reducing agent identified by the instant method.

20060078499, Apr 13, 2006

Dec 1, 2004

11/002769

Rene Hen - Tenafly NJ, US
Luca Santarelli - San Francisco CA, US

A61K 49/00
A61K 31/7072

424009200, 514049000

This invention provides methods for determining whether an agent, known to upregulate the sonic hedgehog pathway, increases brain progenitor cell division in a subject. Furthermore, this invention provides methods for treating anxiety, depression, a cognitive disorder or a neuro-degenerative disorder or inhibiting the onset of anxiety, depression or a cognitive disorder by administering to an afflicted subject a therapeutically or prophylactically effective amount of the agent known to upregulate the sonic hedgehog pathway. Finally, this invention provides methods for treating anxiety, depression, a cognitive disorder or a neuro-degenerative disorder or inhibiting the onset of anxiety, depression or a cognitive disorder by administering to an afflicted subject a therapeutically or prophylactically effective amount of Hh-Ag 1.1, Hh-Ag 1.2, Hh-Ag 1.3, or a derivative of Hh-Ag 1.1, Hh-Ag 1.2 or Hh-Ag 1.3.

20060116392, Jun 1, 2006

Jun 3, 2005

11/144421

Rene Hen - Tenafly NJ, US
Luca Santarelli - San Francisco CA, US
Cristina Alberini - New York NY, US

A61K 31/4745

514291000

This invention provides a method for treating a subject afflicted with an anxiety disorder whose symptoms are exacerbated by the subject's exposure to a predetermined eliciting event, which method comprises administering to the subject a therapeutically effective amount of a protein synthesis inhibitor before, during the time, and/or after the subject intentionally recalls the eliciting event. Furthermore, this invention provides a method for inhibiting in a subject the onset of an anxiety disorder in response to an anxiety disorder-causing event. Finally, this invention provides a related article of manufacture.

20110296540, Dec 1, 2011

Dec 1, 2009

13/131558

Rene Hen - Tenafly NJ, US
Jingwen Wang - New york NY, US
Eduardo David Leonardo - River Edge NJ, US
Jesse Richardson-Jones - New York NY, US

G01N 33/48
A01K 67/00
G01N 33/82
A61K 49/00
C12Q 1/68

800 3, 424 91, 435 612, 435 75, 800 9

This invention provides a method for identifying a small molecule as an antidepressant, a method for identifying a small molecule as an anxiolytic, and a method for identifying a small molecule as able to increase dendritic arborization, decrease expression of an immaturity marker, increase expression of a maturity marker, or enhance artificial cerebrospinal fluid-type long-term potentiation in central nervous system. This invention also provides a transgenic mouse model for SSRI-non-responders.

20130061343, Mar 7, 2013

Feb 8, 2011

13/577281

Rene Hen - Tenafly NJ, US
Kenji Tanaka - Okazak, JP

C12N 15/85
C12P 19/34
C12N 5/10

800 21, 4353201, 435325, 435 913

Disclosed is a FAST (Flexible Accelerated STOP TetO-knockin) system, an efficient method for manipulating gene expression in vivo to rapidly screen animal models of disease. This invention further discloses a single gene targeting event yielding 2 distinct knockin mice—STOP-tetO and tetO knockin—which permit generation of multiple strains with variable expression patterns: 1) knockout, 2) Cre-mediated rescue; 3) tTA-mediated misexpression; 4) tTA-mediated overexpression; and 5) tTS-mediated conditional knockout/knockdown. Using the FAST system, multiple gain- and loss-of-function strains can therefore be generated on a timescale not previously achievable. These strains can then be screened for clinically-relevant abnormalities. The flexibility and broad applicability of the FAST system is demonstrated by targeting several genes encoding proteins implicated in neuropsychiatric disorders: Mlc1, Neuroligin 3, the serotonin 1A receptor, and the serotonin 1B receptor.